EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting

Federica Lo Prinzi, Federico Rossari, Marianna Silletta, Silvia Camera, Silvia Foti, Mara Persano, Francesco Vitiello, Emanuela Di Giacomo, Mariam Grazia Polito, Margherita Rimini, Andrea Casadei-Gardini

Targeted Oncology · 2025-07 · 20 (4) · 707-713

DOI: 10.1007/s11523-025-01161-5 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Targeted Oncology, online erschienen am 23.06.2025. Verfasst von Federica Lo Prinzi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128, Rome, Italy. Hauptthemen laut MEDLINE: Bevacizumab, Carcinoma, Hepatocellular, Liver Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There are no studies that directly compare atezolizumab plus bevacizumab and tremelimumab plus durvalumab (STRIDE), two first-line options for the systemic therapy of advanced hepatocarcinoma (HCC). OBJECTIVE: We conducted a real-world retrospective analysis to compare the clinical efficacies of these two regimens. PATIENTS AND METHODS: Using TriNetX data on patients with HCC at Barcelona Clinic Liver Cancer (BCLC) stages B or C, the analysis included patients treated with atezolizumab plus bevacizumab or with the STRIDE regimen. The primary endpoint was overall survival (OS) comparing the two treatment groups. RESULTS: Before applying propensity-score matching, a total of 2,307 consecutive patients were identified. Among them, 1,998 received atezolizumab plus bevacizumab, and 309 were treated with STRIDE. After matching, 618 patients remained, with 309 in each cohort. The analysis showed no significant difference between the two treatments: median OS was 15.4 months (95% confidence interval (CI) 14.7-51.6) and 15.5 months (95% CI 15.0-47.0) for patients treated with atezolizumab plus bevacizumab versus STRIDE, respectively (HR 0.94; 95% CI 0.73-1.22, p = 0.67). The univariate analyses of baseline clinical and laboratory characteristics indicated that the only differentiating factor between the two regimens was better survival for females receiving atezolizumab plus bevacizumab (HR 1.77; 95% CI 1.00-3.16, p = 0.04). CONCLUSIONS: Atezolizumab plus bevacizumab and STRIDE demonstrated no statistical difference in OS, showing them to be equally valid alternatives for patients with advanced HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabCarcinoma, HepatocellularLiver NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsAntibodies, MonoclonalHumansFemaleMaleMiddle AgedRetrospective StudiesAgedAdult

Substanzen

BevacizumabatezolizumabAntibodies, Monoclonal, HumanizedtremelimumabdurvalumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128, Rome, Italy.
  • Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
  • Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy. casadeigardini@gmail.com.

Zitieren

APA

Lo Prinzi, F., Rossari, F., Silletta, M., Camera, S., Foti, S., Persano, M., Vitiello, F., Di Giacomo, E., Polito, M. G., Rimini, M., & Casadei-Gardini, A. (2025). Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting. Targeted Oncology, 20(4), 707-713. https://doi.org/10.1007/s11523-025-01161-5

Vancouver

Lo Prinzi F, Rossari F, Silletta M, Camera S, Foti S, Persano M, et al. Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting. Targeted Oncology. 2025;20(4):707-713. doi:10.1007/s11523-025-01161-5

BibTeX
@article{LoPrinzi2025,
  author = {Lo Prinzi, Federica and Rossari, Federico and Silletta, Marianna and Camera, Silvia and Foti, Silvia and Persano, Mara and Vitiello, Francesco and Di Giacomo, Emanuela and Polito, Mariam Grazia and Rimini, Margherita and Casadei-Gardini, Andrea},
  title = {Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting},
  journal = {Targeted Oncology},
  year = {2025},
  volume = {20},
  number = {4},
  pages = {707--713},
  doi = {10.1007/s11523-025-01161-5}
}
Kostenlos starten →